About Technology Issues FAQ

Links

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues — Distribution of the number of citations over years.

site/software © exaly; All materials licenced under CC by-SA.